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Recently, we have described a lineage 2 attenuated WN virus suitable for the development of a live WN vaccine. To design vaccine candidates
with an improved immunogenicity, we assembled an infectious clone of the NY99 strain and created several chimeric constructs with reciprocal
exchanges of structural protein genes between attenuated W956 and virulent NY99 and investigated their biological properties. Our data indicated
that, while the growth rates of NY99 and chimeric viruses in tissue culture are determined primarily by properties of the structural proteins,
determinants responsible for a highly cytopathic phenotype of NY99 or lack thereof for W956 are located within the nonstructural protein region
of the WN genome. The high virulence of NY99 and the attenuated phenotype of W956 were found to be associated with determinants in the
nonstructural region. Chimeric viruses carrying the NY99 structural proteins were attenuated in neuroinvasiveness and demonstrated an
immunogenicity superior to W956.
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West Nile (WN) virus isolated over 60 years ago (the
prototype B956 strain; Smithburn et al., 1940) has been known
in Europe and theMiddle East for decades as a causative agent of
self-limiting epidemics and epizootics (Murgue et al., 2001;
Savage et al., 1999). Since its sudden emergence in the U.S.
(Lanciotti et al., 1999), hundreds of human mortality cases and
thousands of confirmed illness cases have been reported to the
CDC (2005). Although highly related to certain strains
circulating in the Middle East, the NY99 strain is perhaps the
most pathogenic and virulent WN strain known to date (Monath,
2001), especially for mice that succumb to encephalitis after
peripheral inoculation of very small doses (Beasley et al., 2002).
In humans, WN infection is often inapparent or occurs as a
mild febrile disease (Monath and Heinz, 1996). However, this
virus was also associated with severe neurological symptoms
(Flatau et al., 1981; Smithburn et al., 1940); recent outbreaks of
WN infection were characterized by an increased CNS
involvement (Roehrig et al., 2002; Solomon and Vaughn,
2002). In the mouse model, in which flaviviruses are inherently⁎ Corresponding author. Fax: +1 785 864 5294.
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doi:10.1016/j.virol.2006.02.013neurovirulent, both neurovirulence and neuroinvasiveness have
been positively associated with determinants in the envelope
proteins (Cecilia and Gould, 1991; Chambers et al., 1999;
Gualano et al., 1998; Hasegawa et al., 1992; Holzmann et al.,
1990, 1997; Jiang et al., 1993; McMinn, 1997; Pletnev et al.,
1992; Pletnev et al., 1993). Other evidence indicates that
mutations in other parts of the flavivirus genome can also
contribute to loss or acquisition of neurovirulence (Butrapet et
al., 2000; Duarte dos Santos et al., 2000; Dunster et al., 1999;
Muylaert et al., 1996; Ni et al., 1995; Xie et al., 1998). Based on
serological data and genetic characterization, West Nile viruses
have been grouped into at least two distinct lineages (Berthet et
al., 1997; Price and O'Leary, 1967). Representatives with
moderate and high virulence have been found in both WN virus
groups (Beasley et al., 2002). The NY99 strain belongs to
lineage 1, which also includes other WN strains that have been
associated with human and equine outbreaks (Roehrig et al.,
2002). The envelope protein (E) of many flaviviruses is
glycosylated, and WN virus is not an exception to this rule,
although a few non-glycosylated strains have been identified
(Beasley et al., 2001; Berthet et al., 1997; Wengler et al., 1985).
The importance of E glycosylation for expression of the virulent
phenotype of lineage 1 WN viruses has been demonstrated
experimentally (Beasley et al., 2005; Shirato et al., 2004).
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sylation on the WN virulence in mice or on its infectivity in cell
culture has been reported as well (Chambers et al., 1998; Hanna
et al., 2005).
A number of subunit or recombinant WN vaccines for
veterinary and human use are currently under development
(Kahler, 2003; Lai and Monath, 2003; Ng et al., 2003; Nusbaum
et al., 2003; Pletnev et al., 2002; Tesh et al., 2002). In contrast to
subunit or inactivated vaccines, a live WN vaccine may be
expected to elicit a long lasting balanced humoral- and cell-
mediated immune response normally seen after YF17D
vaccination (Yamshchikov et al., 2005). However, the high
virulence and pathogenicity of the NY99 strain (Beasley et al.,
2002; Roehrig et al., 2002) make it questionable for use in
development of a live-attenuated WN vaccine. Recently, we
have reported characterization of a lineage 2 WN isolate, W956
(Yamshchikov et al., 2004), which appears sufficiently
attenuated, immunogenic and cross-protective to be considered
as a candidate for further development of live WN vaccine. One
may expect that increasing the antigenic match to the strain
circulating in the U.S. could improve the immunogenicity of a
candidate for vaccine development. As a first step in evaluating
this approach, we have assembled an infectious clone of the
NY99 strain and created several chimeric viruses carrying
reciprocal exchanges of the W956 and NY99 structural protein
genes. In this study, we compared biological properties of the
parent and chimeric viruses in tissue culture and in the mouse
model and evaluated their immunogenicity in mice.
Results
Design of NY99 and other infectious DNA constructs
Earlier we reported the assembly of an infectious clone of
WN lineage 2 virus (pSP6W956; Yamshchikov et al., 2001b).
To simplify handling, it was converted to the infectious DNA
(iDNA) format by engineering the CMV promoter transcriptionFig. 1. Parent and chimeric infectious DNA constructs used in this study. A schematic
proteins (Lindenbach and Rice, 2001) is shown on the top. Approximate locations
genome positions of intron insertions are shown below. CMV—human cytomegalov
hormone transcription termination and polyadenylation sequence. For clarity, the scstart to the beginning of WN genome cDNA. The antisense
strand hepatitis δ ribozyme followed by the bovine growth
hormone transcription termination signal (BG) was engineered
to the end of WN cDNA for an increased fidelity of 3′-end
formation, giving rise to the final construct pCMVW956δBG
(further referred to as pCMVW956; Fig. 1).
A NY99 infectious clone was assembled using genetic
material of isolate 385–99 (Xiao et al., 2001) according to the
strategy we developed earlier (Yamshchikov et al., 2001a)
with artificial introns inserted into viral genome cDNA for
stabilization of the plasmid in E. coli. Upon transfection of
eukaryotic cells, introns are spliced out resulting in precise
restoration of viral ORF and initiation of the viral infectious
cycle. Two such introns were inserted at positions 2383 and
3472 of the NY99 genome. The infectivity of the final
construct CMVNY99(i2383i3472)δBG (further referred to as
CMVNY99) is demonstrated in Fig. 2. Except for the two
introns and an introduced MfeI site at the end of E gene,
NY99 genome cDNA in CMVNY99 is authentic to the 385–
99 genome (GenBank #DQ211652). The presence of both
i2384 and i3472 was found to be crucial for the stability of
the plasmid.
The pCMVW956 and pCMVNY99 constructs were
used to create plasmids carrying reciprocal exchanges of
the structural protein genes of two viruses (Fig. 1). The
pCMV[CprMENY99]W956 chimera carries genes of all
NY99 structural proteins instead of those of W956. In the
pCMV[prMENY99]W956 chimera, only the prM-E region of
NY99 (not including its prM signal sequence) from position
466 to position 2405 was used to replace the corresponding
region in the pCMVW956 construct. The E protein of NY99
is glycosylated at the NYS site (E154–156). A variant of
pCMV[prMENY99]W956 was prepared that encodes NY99 E
in which this glycosylation site was mutated (NYS → SYS).
The last chimeric construct pCMV[CprMEW956]NY99 was
created by transferring the BglII–MfeI fragment coding for
CprME of W956 into pCMVNY99.representation of the WN virus genome with genes of recognized virus-specific
of the intron present in particular constructs are marked by a filled arrowhead,
irus promoter/enhancer, δ—antisense hepatitis δ ribozyme, BG—bovine growth
hematic is not drawn exactly to the scale.
Fig. 3. PAGE analysis of proteins specified by parent and chimeric viruses.
[35S]-labeled WN-specific proteins were recovered by immunoprecipitation (left
panel) from media 24 h after infection of Vero with specified viruses used at
MOI = 10. The same samples after deglycosylation with PNGase F are shown on
the right panel. Virus designations are the same as in text. WN glycoproteins are
identified on the left and right; pr(M) is the glycosylated amino terminal part of
prM that is cleaved during virus maturation and is secreted from infected cells.
Fig. 2. Virus recovery from the WN infectious DNA. WN antigens in transfected cells were visualized by indirect immunofluorescence with WN-specific HMAF and
anti-mouse IgG-fluorescein conjugate. Vero cells 24 h (left) and 40 h (right) after transfection with pCMVNY99 and Lipofectamine 2000 (Invitrogen).
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All constructs described above were infectious in tissue
culture, that is, lipid-mediated direct transfection of Vero,
BHK or mosquito C6/36 cells with either of these plasmids
resulted in the establishment of a productive infection. Foci of
virus multiplication were easily detectable by indirect
immunofluorescence 24 h after transfection, and by 40 h
after transfection, the entire monolayer was infected (Fig. 2
for pCMVNY99). The specific infectivity of iDNA was in the
range 3–8 × 106 pfu/μg DNA in Vero cells. For brevity,
viruses recovered from the iDNA constructs (shown in
parentheses) were designated W956 (pSP6W956 or
pCMVW956), NY99REC (pCMVNY99), NY99CME (pCMV
[CprMENY99]W956), NY99ME (pCMV[prMENY99]W956),
NY99ME(SYS) (pCMV[prMENY99]W956 with the mutated
glycosylation site in E) and W956CME (pCMV[CprMEW956]
NY99). Genomes of all virus isolates were completely
sequenced at Vero passage 2 and demonstrated the expected
nucleotide sequences constructed on the basis of W956
(GenBank #M12294) and 385–99 (GenBank #DQ211652)
genome sequences. In addition, the E gene of NY99ME(SYS)
was sequenced at Vero passage 3 and no signs of reversion to
the wild type sequence were found.
The glycosylation status of glycoproteins specified by the
parent and chimeric viruses was verified by immunoprecip-
itation, deglycosylation with PNGase F and SDS-PAGE. The
prM and NS1 proteins of both NY99 and W956 each carry
glycosylation sites, and all are glycosylated as shown in Fig.
3. While the E protein of NY99 is also glycosylated at the
NYST site (position 154–157 in the E protein), the E protein
of W956 (as well as its parent 956D117B3 and its ancestor
B956) carries a deletion of the entire 4 aa site. Accordingly,
the E protein of W956 is not glycosylated (Fig. 3). As
expected, NY99ME(SYS) also produced non-glycosylated E
(data not shown). In contrast, cells infected with either NY99
or both chimeric NY99CME and NY99ME produce glycosy-
lated E (Fig. 3). WN HMAF used for immunoprecipitation
was prepared against W956 (Yamshchikov et al., 1997,
2001b). It appears less efficient in immunoprecipitation of
secreted NS1 of NY99, which is represented by a diffuse
band due to the heterogeneity of the oligosaccharide moiety(Fig. 3, left) and is better revealed after deglycosylation (Fig.
3, right). Both chimeric viruses specify NS1 of W956, which
is efficiently recovered as for W956 (Fig. 3).
The growth characteristics of viruses at passage 2 were
compared in Vero cells. As shown in Fig. 4A, NY99CME and
NY99ME accumulated at the rate essentially similar to NY99. To
the opposite, the growth curve of the W956CME chimera that
carries the structural protein genes of W956 and the rest of the
genome from NY99 was found to be very similar to W956 (Fig.
4B). For comparison, Fig. 4B shows a single step growth curve
for NY99REC that was recovered from the parent infectious
DNA construct pCMVNY99. The growth rate of NY99REC is
very similar to parent NY99 (Fig. 4A). We did not measure
specifically the growth rate of NY99ME(SYS). Based on the titer
of the passage 2 progeny (1.3 × 107 pfu/ml) attained by 4 days
Fig. 4. Growth characteristics of parent and chimeric viruses. Vero cells
were infected at MOI = 1, viral progeny was harvested at specified time
intervals and titers were determined in Vero. NY99CME—virus recovered
from pCMV[CprMENY99]W956, NY99ME—virus recovered from pCMV
[prMENY99]W956, NY99REC—virus recovered from pCMVNY99, W956—
virus recovered from pCMVW956, and W956CME—virus recovered from
(pCMV[CprMEW956]NY99.
Fig. 5. Cytopathic properties and plaque morphology of parent and recovered viruses.
specified viruses and incubated under 1% methyl cellulose for 5 days. Selected wells
fixed in methanol-acetic acid at −20 °C and immunostained with WN-specific HM
Visualized foci were photographed in visible light.
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resemble W956 and W956CME.
The prominent phenotypic difference between parent NY99
and W956 is the high cytopathic effect in Vero cells that is
characteristic for the former and is absent for the latter (Fig. 5).
Surprisingly, both NY99CME and NY99ME carrying the
structural protein genes of NY99 have retained the phenotype
of W956, which does not form distinctive plaques in Vero cells
(Fig. 5, the upper panel). Foci of virus multiplication are barely
visible on fixed and stained monolayers as pale areas without
discernible cell destruction. Immunohistochemical staining of
fixed cells shows that NY99CME and NY99ME actually form
larger foci, which is indicative of a higher efficiency of viral
spread, resembling NY99 more than W956 (Fig. 5, the lower
panel). This phenotypic marker agrees with the higher
accumulation rates of both NY99CME and NY99ME demon-
strated above, which is characteristic for NY99. In contrast,
W956CME carrying the structural protein genes of W956 in the
NY99 genome displays an essentially reversed phenotype. It
demonstrates a clearly cytopathic phenotype of NY99 (Fig. 5,
the upper panel), yet by its growth rate (Fig. 4B) and by the
plaque/foci size (Fig. 5, the lower panel), it resembles W956.
Virulence and pathogenicity of recovered viruses
Peripheral virulence of the parent and chimeric viruses was
assessed in 4-week-old outbred Swiss Webster mice, which
were infected i.m. with serial 10-fold dilutions of viral stocks.
LD50 values were calculated by the Reed&Muench method
(Burleson et al., 1992) based on survival 2 weeks after
inoculation. As shown in Table 1, the attenuated phenotype of
W956 (i.m. LD50 = 0.9 × 10
6 pfu) is contrasted by the high
virulence of NY99 (i.m. LD50 = 17 pfu). Infection with NY99
uniformly resulted in rapidly progressing encephalitis accom-
panied by multiple paralysis and resolved by death often in less
than 12 h after onset of neurological symptoms. This is
summarized by a short average survival time (AST) with a
rather little dependence on the virus dose and insignificant
deviation among animals, as shown in Table 1. Permanent
sequelae, such as hind limb paralysis, were often observedConfluent monolayers of Vero cells were infected with serial 10-fold dilutions of
were either fixed in 10% formalin and stained with methyl violet (upper panel) or
AF followed by a peroxidase conjugate and the DAB substrate (lower panel).
Table 1
Virulence of the parent viruses in mice
W956 a D/T b %b AST NY99 a D/T b %b AST
2.6 × 106 3/6 50 10.7 ± 2.5 – – – –
2.6 × 105 2/6 33 9.5 ± 2.1 8.8 × 104 6/6 100 7.5 ± 0.8
2.6 × 104 1/6 17 13.0 ± 0.0 8.8 × 103 6/6 100 8.0 ± 1.3
2.6 × 103 0/6 0 N/A 8.8 × 102 5/6 83 8.0 ± 0.8
2.6 × 102 0/6 0 N/A 8.8 × 101 5/6 83 8.0 ± 1.4
2.6 × 101 0/6 0 N/A 8.8 × 100 3/6 50 9.0 ± 1.0
LD50 = 0.9 × 10
6 pfu LD50 = 1.7 × 10
1 pfu
a Intramuscular injection, pfu/mouse.
b Mortality at 2 weeks after inoculation.
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W956 resolved in 2–3 days and was characterized by
immobility, anorexia and a substantial weight loss, but paralytic
symptoms were uncommon. Infection with lethal doses of
W956 was characterized by overall longer AST, which also did
not show a clear dependence on the virus dose but was
characterized by a substantial deviation between animals (Table
1). Virus was isolated from brains of all succumbed mice
indicating that W956 is neuroinvasive when administered in
high doses. Mice, which became symptomatic, apparently could
not contain the infection and usually did not survive; those that
have survived even high doses of W956 usually did not
demonstrate visibly identifiable illness.
Transfer of the NY99 structural protein genes into the
genome of attenuated W956 did not result in transfer of the
NY99 highly virulent phenotype, although an about 100-fold
increase in virulence was observed based on values of LD50
shown in Tables 1 and 2. Mice inoculated with either NY99CME
and NY99ME chimeric viruses demonstrated scattered deaths
with a lack of clear dependence on the virus dose, which did not
allow to calculate reliable LD50 values. For either chimeric
virus, however, ASTwas more dependent on the virus dose. As
shown in Table 2, in the upper dose range, AST was closer to
that after NY99 infection, but it gradually increased to resemble
W956 in the lower dose range of chimeric viruses. Elimination
of the glycosylation site in NY99ME by (NYS→ SYS) mutation
completely eliminated the observed ∼100-fold increase in
virulence (Table 2). The resulting NY99ME(SYS) virusTable 2
Virulence of the chimeric viruses in mice
NY99CME
a D/T b %b ASTc NY99ME
a D/T b %b ASTc NY
2.2 × 106 5/6 83 7.3 ± 2.9 5.75 × 106 4/6 67 7.8 ± 2.2 1.3
2.2 × 105 3/6 50 7.7 ± 0.6 5.75 × 105 1/6 17 8.0 ± 0.0 1.3
2.2 × 104 3/6 50 9.3 ± 2.1 5.75 × 104 6/6 100 9.7 ± 1.5 1.3
2.2 × 103 3/6 50 10.0 ± 0.0 5.75 × 103 2/6 33 9.5 ± 0.7 1.3
2.2 × 102 0/6 0 – 5.75 × 102 2/6 33 8.5 ± 0.7 1.3
2.2 × 101 3/6 50 10.3 ± 0.6 5.75 × 101 4/6 67 11.5 ± 2.4 1.3
– – – – – – – – –
– – – – – – – – –
LD50 = 1.0 × 10
4 pfu d LD50 = 1.2 × 10
4 pfu d LD
a Intramuscular injection, pfu/mouse.
b Mortality at 2 weeks after inoculation.
c Average survival time.
d Reliable values cannot be calculated.
e LD50 cannot be calculated because 50% endpoint could not be reached.appeared as attenuated as W956 despite the presence of NY99
prM-E. We could not calculate LD50 of this virus because
mortality did not exceed 50% at the maximal dose we could
administer. Both chimeric viruses carrying glycosylated NY99
E produced symptomatic patterns resembling either NY99
(paralytic encephalitis) or W956 (no paralytic symptoms). We
could not identify a statistically significant correlation of the
particular symptomatic pattern and the dose. The only mouse
that succumbed to the highest dose of NY99ME(SYS)
demonstrated a symptomatic pattern undistinguishable from
that caused by W956, although this single case is insufficient to
draw conclusions. The survival time was similar to W956 as
well.
Surprisingly, transfer of the structural protein genes from
attenuated W956 into the genome of virulent NY99 produced a
chimeric virus that demonstrated essentially the same virulence
in mice as parent NY99 (Table 2). Infection with W956CME
uniformly produced a rapidly developing paralytic encephalitis.
Similarly to infection with NY99, a sudden onset of symptoms
was followed by terminal resolution in less than 12 h. Opposite
to the two other chimeric viruses, the AST dependence on the
dose of W956CME was very similar to that of NY99 (compare
AST in Tables 1 and 2).
Immune response to chimeric viruses
Mice that survived infection with chimeric viruses
NY99CME, NY99ME and NY99ME(SYS) were bled at 4 weeks
after inoculation, and immune sera were combined in each virus
dose group to obtain averaged results. The presence of virus-
specific antibodies was evaluated by ELISA with the NY99
viral antigen and in plaque reduction-neutralization titer
(PRNT) assays with NY99 virus. For comparison, we also
evaluated the humoral immune response in mice that survived
infection with W956. Similar comparison with NY99 could not
be done due to the low survival rate of infected mice; some of
the few animals that survived the lowest NY99 doses did not
demonstrate any virus-specific immunity and likely did not
experience infection. Although animals demonstrated high titers
of WN-specific IgG 4 weeks after inoculation with all tested99ME(SYS)
a D/T b %b ASTc W956CME
a D/T b %b ASTc
× 106 1/4 25 10.0 ± 0.0 3.1 × 106 5/6 83 6.6 ± 0.9
× 105 0/4 0 – 3.1 × 105 6/6 100 6.8 ± 0.8
× 104 0/4 0 – 3.1 × 104 6/6 100 8.0 ± 0.9
× 103 0/4 0 – 3.1 × 103 6/6 100 8.5 ± 0.5
× 102 0/4 0 – 3.1 × 102 6/6 100 8.2 ± 0.4
× 101 0/4 0 – 3.1 × 101 6/9 66 9.2 ± 1.7
– – – 3.1 × 100 0/3 0 N/A
– – – 3.1 × 10−1 0/3 0 N/A
50 > 1.3 × 10
6 pfu e LD50 = 2.1 × 10
1 pfu
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NY99CME, NY99ME and NY99ME(SYS) developed, in general,
a 4- to 10-fold stronger NY99-specific humoral response.
Comparison of NY99 neutralizing titers shown in Table 3
demonstrates that all chimeric viruses have induced titers of
NY99 neutralizing antibodies superior to those caused byW956
immunization. The difference is especially visible in the lower
dose range. While at the lowest W956 dose used animals did not
demonstrate any detectable immunity indicating lack of
infection, all chimeric viruses at comparable (NY99CME and
NY99ME) and even lower doses (NY99ME(SYS)) induced
strong virus-specific and neutralizing immune response. This
suggests that virions containing NY99 structural proteins
possess a higher infectivity resulting in a lower effective
infectious dose. Accordingly, all animals that demonstrated the
presence of neutralizing antibodies have survived subsequent
challenge with 100LD50 of NY99. There were no survivors in
the lowest W956 dose group as well as among control
unimmunized mice.
Discussion
Earlier, we described a highly attenuated lineage 2 isolate
WN1415 that is highly immunogenic and cross-protective
against NY99. We reasoned that the suitability of this isolate
(referred here as W956 to indicate its relation to the prototype
B956 strain) for WN vaccine development can be substantially
increased by combining its attenuated nature with the antigenic
identity of NY99. To test that, we have created chimeric lineage
1 and lineage 2 West Nile viruses and investigated their
biological properties in tissue culture as well as virulence and
immunogenicity in mice. Chimeric iDNA carrying reciprocal
exchanges of the structural protein genes of two viruses was
assembled using corresponding lineage 1 and lineage 2
infectious DNA constructs pCMVNY99 and pCMVW956.
Growth properties of the parent (NY99 and W956) and the
recovered (NY99REC, NY99CME, NY99ME and W956CME)
viruses were examined in Vero cells. As expected, NY99,
NY99REC, NY99CME and NY99ME that carry the prM-E genes
of NY99 demonstrated the essentially similar growth character-
istics. In contrast, the growth rate of W956CME was very similar
to W956 with peak titers lower than observed for NY99REC byTable 3
Development of NY99-specific humoral immunity a
WN1415 b NY99CME
b
Dose ELISAc PRNTd Dose ELISAc PRNTd
2.6 × 106 80,000 320 2.2 × 106 10,000 80
2.6 × 105 32,000 120 2.2 × 105 >128,000 2133
2.6 × 104 32,000 60 2.2 × 104 >128,000 1707
2.6 × 103 32,000 240 2.2 × 103 128,000 640
2.6 × 102 32,000 60 2.2 × 102 80,000 640
2.6 × 101 0 0 2.2 × 101 80,000 320
a Serum samples at 4 weeks post-inoculation combined for each virus dose group
b Immunizing virus administered i.m. at the specified doses as determined by bac
c Endpoint dilution titers of combined for each dose group serum samples assaye
d Endpoint dilution plaque reduction-neutralization titers of combined for each do1–2 logs. The differences in the growth rate correlate with the
plaque size or the size of virus multiplication foci visualized by
immunohistochemical staining. The combined evidence indi-
cates that the higher growth rate characteristic for NY99 is
determined by the properties of its structural proteins. In
contrast, determinants that are responsible for the cytopathic
effect of NY99 (or lack thereof for W956) are associated with
the nonstructural proteins (NSps). This conclusion is strongly
supported by the essentially reversed phenotype of W956CME
that carries the structural protein genes of W956 in the NY99
genome. Determinants or mechanisms of flavivirus cytopathi-
city are not clearly defined. For WN viruses, either necrosis or
apoptosis has been observed depending on the virus dose (Chu
and Ng, 2003). A number of evidence implicated NS3 in
induction of apoptosis by dengue and WN viruses (Duarte dos
Santos et al., 2000; Ramanathan et al., 2006). Although 3 and
26 aa differences distinguish NS2B and NS3 of W956 and
NY99, all these are shared by noncytopathic W956 and its
cytopathic ancestor B956 (Yamshchikov et al., 2004), indicat-
ing that neither the NS2B–NS3 protease or NS3 alone is not
responsible for the observed differences in cytopathicity.
Both neuroinvasiveness and neurovirulence of flaviviruses
in the mouse model have been associated with determinants in
the envelope protein (Cecilia and Gould, 1991; Chambers et al.,
1999; Gualano et al., 1998; Hasegawa et al., 1992; Holzmann et
al., 1990, 1997; Jiang et al., 1993; McMinn, 1997; Pletnev et al.,
1992, 1993). Thus, one could anticipate that transfer of the
NY99 structural protein genes will result in transfer of the
NY99 highly virulent phenotype. However, this was not found
to be the case, although an about 100-fold increase in virulence
was observed based on LD50 values of attenuated W956 and
both chimeric viruses. It needs to be underscored, however, that
LD50 values for NY99CME and NY99ME could not be reliably
determined by the Reed&Muench method due to scattered
mortality without clear dependence on the virus dose, and
calculated values should be considered as approximate. Both
chimeric viruses demonstrated so-called attenuated neuroinva-
sive phenotype with characteristic lack of clear dose-dependent
response (Arroyo et al., 2001; Beasley et al., 2005; Shirato et al.,
2004). It has been shown that neuroinvasiveness of NY99 and
other lineage 1 strains at least in part is determined by the
glycosylation status of the E protein (Beasley et al., 2005;NY99ME
b NY99ME(SYS)
b
Dose ELISAc PRNTd Dose ELISAc PRNTd
5.8 × 106 >128,000 1280 1.3 × 106 >128,000 3200
5.8 × 105 >128,000 1920 1.3 × 105 >128,000 1280
5.8 × 104 ND ND 1.3 × 104 >128,000 480
5.8 × 103 128,000 3840 1.3 × 103 128,000 640
5.8 × 102 32,000 1920 1.3 × 102 64,000 240
5.8 × 101 32,000 960 1.3 × 101 128,000 480
and assayed in triplicate.
k-titration.
d in triplicate.
se group serum samples assayed in triplicate.
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associated with a reduced infectivity of WNV of either lineage
in tissue culture (Hanna et al., 2005) and with attenuation of the
mouse virulence for lineage 1 viruses (Chambers et al., 1998).
Molecularly cloned W956, parent 956D117B3 and their
ancestor B956, which displayed various levels of attenuation
(Yamshchikov et al., 2004), carry a deletion of four amino acids
that compose the E154–157 glycosylation locus (NYST in the
majority of lineage 1 viruses). Replacement of the authentic E
gene in W956 with the gene of glycosylated E from NY99
produced NY99CME and NY99ME with the increased virulence.
When the glycosylation site in NY99ME was eliminated by
NYS → SYS mutagenesis, this increase in virulence was
completely eliminated since the resulting NY99ME(SYS)
appeared as attenuated as WN956 despite the presence of
NY99 prM-E. This does not contradict the existing evidence
supporting the importance of E glycosylation for expression of
the virulent phenotype. However, transfer of the gene coding for
non-glycosylated E from W956 into the NY99 genome
produced the W956CME chimeric virus with essentially the
same neuroinvasiveness and virulence in mice as NY99 despite
its somewhat slower growth in tissue culture. Thus, the effect of
E glycosylation on virulence and/or neuroinvasiveness is most
likely virus-specific.
The combined evidence indicates that determinants of
NY99 high virulence, as well as the genetic basis of W956
attenuation, are found in the nonstructural protein region.
Recently reported evidence indicates that NY99 interferes with
IFN signaling pathways in infected cells (Guo et al., 2005; Liu
et al., 2005; Munoz-Jordan et al., 2005; Pantelic et al., 2005;
Scholle and Mason, 2005). While reports contradict each other
in regard to possible mechanisms and roles of individual
proteins, there is a general agreement on the crucial role of
NY99 NSps in such interference. It remains to be seen,
however, whether such interference play an important role in
NY99 pathogenesis in vivo. Another phenotypic marker
shared between highly virulent NY99 and W956CME is the
cytopathic nature of both viruses. Recent demonstration of the
specific role that toll-like receptor 3 (Tlr3) plays in mediating
NY99 neuroinvasion in mice (Wang et al., 2004) leads to a
tempting suggestion. Tlr3 recognizes dsRNA (Schroder and
Bowie, 2005) that is produced as an intermediate during
replication of many RNA viruses, including WN virus. The
high cytopathicity of NY99 may contribute to its neuroinva-
sive phenotype by increasing the release of dsRNA from
infected cells. When compounded by interference with IFN
signaling, which may have broad consequences from an
inefficient early control of viremia due to dampened innate
immune response to a cytokine-induced compromise of the
blood brain barrier (Veldhuis et al., 2003), the high
cytopathicity of NY99 may constitute a significant factor of
its virulence. Although this seems a feasible explanation for
the apparent association of virulence and cytopathicity that we
have observed in this study, it remains to be experimentally
supported.
The above conclusion implies that attenuation of highly
virulent NY99 by mutagenesis of the E protein may not beadequate to yield a sufficiently safe vaccine. Even if a very
high level of attenuation can be achieved by mutations
introduced in E at multiple loci, the function of the E protein
is directly connected to the virus infectivity and is under a
high selective pressure for reversion to the maximal
functionality. With virulence determinants being in the NSp
region, rapid selection of viruses with a higher infectivity may
result in rapid reversion to a highly virulent phenotype. Such
consideration corroborates the suitability of the chimeric
flavivirus approach (Lai and Monath, 2003) for development
of a WN vaccine, in which WN virulence determinants located
in its NSp genome region are eliminated by replacement with
NSp genome regions of attenuated vaccine vectors. We
suggest that utilization of an attenuated WN virus as a viral
vector may offer additional advantages of the highly
homologous nonstructural proteins that carry major flavivirus
T-cell epitopes (Co et al., 2002; Lobigs et al., 1994; Mathew et
al., 1996; Okamoto et al., 1998; Parrish et al., 1991; Spaulding
et al., 1999). Comparison of humoral responses in mice
demonstrated the superior immunogenicity of the chimeric
viruses. Notably, some increase in virulence resulted from
chimerization of attenuated W956 with NY99 prM-E
completely eliminated by removal of the E glycosylation site
without affecting the virus growth rate and its superior
immunogenicity. Although rigorous testing of the genetic
stability of the introduced NYS→ SYS mutation is warranted,
the high immunogenicity, good growth characteristics and the
highly attenuated nature makes W956 and NY99ME(SYS)
suitable for development of WN live vaccines, with the latter
to be more attractive than the former due to closer antigenic
similarity to NY99. Targeted mutagenesis of the E protein may
be utilized to eliminate the residual virulence, for example, by
introducing attenuating mutations found in the Japanese
encephalitis SA14-14-2 vaccine as suggested earlier (Monath,
2001). We are currently in the process of testing these
alternatives.
Materials and methods
DNA manipulation, cloning and characterization of
recombinant constructs
DNA manipulations were done using the standard proce-
dures (Sambrook and Russell, 2001) with commercially
available enzymes in conditions recommended by manufac-
turers. Total RNA from infected cells was isolated using the
RNeasy Mini kit (Qiagen, Valencia, CA). PCR and RT-PCR
amplification was done using high fidelity KOD polymerase
(Novagen, Madison, WI). A set of primers for amplification and
sequencing of 385–99 cDNA fragments was designed on the
basis of the 382–99 sequence (GenBank #AF196835).
Sequencing of cDNA fragments and plasmids was done using
ABI310 Genetic Analyzer (Perkin-Elmer) with the manufac-
turer's kits and protocols. Throughout the study, NIH Guide-
lines for Research involving Recombinant DNA Molecules
were followed. E. coli strain HB101 was used for cloning and
maintenance of recombinant constructs.
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The infectious clone of lineage 2 WN 956D117B3 strain,
here referred to as pSP6W956, has been described earlier
(Yamshchikov et al., 2001b). A 739-bp fragment containing
the CMV promoter/enhancer including its transcription start
was amplified from the pCIneo plasmid (Promega, Madison,
WI). The CMV transcription start was engineered by PCR to
the beginning of the WN genome cDNA, and resulting joint
CMV-5′UTR was used as ClaI–BglII fragment to replace the
corresponding SP6-5′UTR fragment in pSP6W956. A 350-bp
fragment containing the hepatitis δ ribozyme followed by the
bovine growth hormone transcription termination and poly-
adenylation signal (the δBG cassette, Fig. 1) was amplified
from JE infectious DNA reported earlier (Yamshchikov et al.,
2001a) and was inserted at the end of the WN genome cDNA,
with the cleavage site of the ribozyme precisely engineered to
the 3′-end of the WN genome. The resulting pCMVW956 was
characterized by complete sequencing of the WN genome
cDNA insert.
A similar ClaI–BglII CMV-5′UTR joint fragment was
created using 385–99 cDNA, which was used to assemble a
CMV-driven subgenomic replicon construct lacking genes C,
prM and E (positions 162–2352). The δBG cassette was
engineered at the 3′end of the 385–99 genome as above. The C-
prM-E structural protein gene cassette of 385–99, which was
modified by PCR-mediated insertion of a 132 bp intron at
position 2384, and by an introduced MfeI site (position 2405),
was assembled separately. The 132-bp artificial intron carrying
stop codons in three frames was amplified from pCIneo. The
modified structural gene cassettes were inserted as BglII–BspEI
fragments into the 385–99 replicon plasmid replacing the
corresponding fragment carrying the deletion. The final
stabilized pCMVNY99 infectious DNA construct was created
by PCR-mediated insertion of a second copy of the 132 bp
intron at position 3472 into the construct carrying i2384. After
complete sequencing of the 385–99 genome cDNA insert in the
final construct, all 12 revealed mutations have been eliminated
by replacing fragments carrying mutations with the
corresponding fragments amplified from de novo synthesized
cDNA.
Reciprocal exchanges of the C-prM-E genes between
pCMVW956 and pCMVNY99 were done by exchange of the
corresponding BglII–MfeI fragments (from position 89, 8 nt
upstream from the beginning of NY99 and W956 ORF, to
position 2393 in W956 and 2405 in NY99 at the amino terminus
of the NS1 signal sequence). A fragment including only the
prM-E genes of 385–99 was created by PCR-mediated
engineering of the carboxy terminus of the internal prM signal
peptide of W956 (including the signalase cleavage site) to the
amino terminus of mature prM of 385–99 with subsequent
transfer of the chimeric C-prM-E cassette as the BglII–MfeI
fragment.
Mutagenesis of the glycosylation site was done by PCR
using a pair of mutagenizing primers that introduce the N→ S
mutation (…AAC…→ …TCC… in the sense strand) in the NYS
glycosylation site in the NY99 E protein. These primers andprimers flanking unique EcoNI and MfeI sites were used to
amplify a mutagenized fragment from the pCMVNY99
template. Resulting PCR fragment was digested with EcoNI
and MfeI, a 1283-bp fragment was purified on agarose gel and
used to replace the corresponding EcoNI–MfeI fragment in
pCMV[prMENY99]W956). Sequences of all primers used in
this section are available on request.
Cells and viruses
Vero (ATCC CRL-1586) were maintained at 37 °C in a
humidified atmosphere containing 5% CO2 in Dulbecco's
modified Eagle medium (DMEM) supplemented with 5% fetal
calf serum (FCS; Hyclone, Logan, UT) and 1× antibiotic–
antimycotic mixture (Invitrogen, Carlsbad, CA). The molecu-
larly cloned isolate W956 (earlier designated W1415) has been
described (Yamshchikov et al., 2001b, 2004). The 385–99
isolate of the NY99 strain at Vero passage 1 was kindly
provided by R. Tesh (Galveston, TX), and the working stock
(8.8 × 107 pfu/ml) was prepared by additional passage in Vero.
Total RNA isolated from infected cells after harvesting the
passage 2 virus was used to prepare a set of cDNA fragments
covering the entire 385–99 genome.
Recovery of chimeric viruses, determination of virus titers and
characterization of viruses in tissue culture
Transfection of Vero cells with infectious DNA was done
using the Lipofectamine 2000 transfection reagent (Invitrogen,
Carlsbad, CA) according to the manufacturer's protocol.
Briefly, a transfection mixture containing 0.8 μg of DNA and
3 μl of the reagent in 100 μl of Opti-MEM (Invitrogen) was
added to a 70–80% confluent Vero monolayer in a 12-well plate
cluster. After 6–8 h incubation under the normal growth
conditions, the transfection medium was replaced with the fresh
growth medium and incubation was continued for additional 2–
3 days to allow sufficient accumulation of the passage 1
progeny. Working stocks of passage 2 viruses were prepared by
infecting Vero with the passage 1 progeny at MOI = 0.1 and
harvesting the progeny from the medium 4–5 days post-
infection. Titers of viral stocks at passage 2 prepared in Vero
cells were 1.4 × 108 (NY99CME), 5.7 × 10
7 (NY99ME),
1.3 × 107 (NY99ME(SYS)) and 3.1 × 10
7 (W956CME) pfu/ml.
Total RNA isolated from the infected cells was used for RT-
PCR amplification of overlapping cDNA fragments, which
were gel-purified and sequenced as above.
For indirect immunofluorescence, cells were seeded on glass
coverslips in 24-well plate clusters and half of the DNA and
transfection reagent was used under the same conditions. Cells
fixed with acidic methanol were processed for WN-specific
indirect immunofluorescence as described (Yamshchikov et al.,
2001b).
Viral proteins were labeled with [35S]Met 24 h after infection
of Vero with specified viruses at MOI = 10; labeling,
immunoprecipitation, deglycosylation with PNGase F and
PAGE analysis were done as described earlier (Yamshchikov
and Compans, 1993, 1995; Yamshchikov et al., 1997). Virus
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et al., 2004).
The specific infectivities of iDNA constructs, virus cyto-
pathic properties and plaque morphology were analyzed as
described (Yamshchikov et al., 2001a, 2001b, 2004). Briefly,
transfected or infected Vero monolayers were incubated in the
growth medium containing 1% methyl cellulose, washed, fixed
and either stained with methyl violet or immunostained with
WN-specific hyperimmune ascites fluid (HMAF) and the
peroxidase–DAB procedure.
Virus infection and challenge
Three to four-week-old female Swiss Webster outbred mice
purchased from Charles River (Wilmington, MA) were
maintained in a BL3 facility according to the NIH guidelines
and used in IACUC-approved protocols. Mice were infected
into the Tibialis anterior muscle (i.m.) with virus dilutions
prepared in PBS plus 0.2% normal mouse serum and observed
for 3 weeks. Mice that developed the encephalitic syndrome
such as paralysis were euthanized and counted as lethal cases.
LD50 (50% lethal dose) was calculated by the Reed&Muench
method (Burleson et al., 1992). Mice that survived the primary
infection were challenged at 4 weeks with 100 i.m. LD50 of
NY99 virus and were observed for additional 3 weeks.
Analysis of NY99-specific humoral immune response
Endpoint dilution titers of NY99-specific IgG were deter-
mined in triplicate by standard antibody-capture ELISA using
the NY99 viral coating antigen produced from solubilized
pelleted virions as described earlier (Yamshchikov et al., 2004).
Readings that differ by two standard deviations from pre-
immune sera at the same dilution were considered positive.
Titers of neutralizing antibodies were determined using NY99
virus and plaque reduction-neutralization titer (PRNT) micro-
assay (constant virus-variable serum) as described (Yamshchi-
kov et al., 2004, 2005). Briefly, confluent Vero cells in 96-well
microplates were infected in duplicate with 50 pfu of NY99 in
the presence of serially diluted immune sera, incubated for 24 h,
fixed and stained using WN-specific HMAF and ABC
peroxidase–DAB procedure.
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